en · de · es
sr9009-notes.peptides7501.com › News › Background And Receptor Pharmacology — Deep Dive

Background And Receptor Pharmacology — Deep Dive

By Editorial Desk · published 2025-10-13 · last reviewed 2025-12-05 · News

The short version of analytical standard fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Related pages on this site

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Reference notes

The verdict was treated with scepticism by much of the international media and the US Government led by President Jimmy Carter. On 2 February 1978, based on the evidence given at the inquest, the attorney general of the Eastern Cape stated that he would not prosecute the officers. After the inquest, Biko's family brought a civil case against the state; at the advice of their lawyers, they agreed to a settlement of R65,000 (US$78,000) in July 1979. Shortly after the inquest, the South African Medical and Dental Council initiated proceedings against the medical professionals who had been entrusted with Biko's care; eight years later two of the medics were found guilty of improper conduct. The failure of the government-employed doctors to diagnose or treat Biko's injuries has been frequently cited as an example of a repressive state influencing medical practitioners' decisions, and Biko's death as evidence of the need for doctors to serve the needs of patients before those of the state. After the abolition of apartheid and the establishment of a majority government in 1994, a Truth and Reconciliation Commission was established to investigate past human-rights abuses. The commission made plans to investigate Biko's death, but his family petitioned against this on the grounds that the commission could grant amnesty to those responsible, thereby preventing the family's right to justice and redress. In 1996, the Constitutional Court ruled against the family, allowing the investigation to proceed.

== Reading == Cook, T. R.; Zheng, Y.; Stang, P. J. (2013). "Metal-organic frameworks and self-assembled supramolecular coordination complexes: Comparing and contrasting the design, synthesis, and functionality of metal-organic materials". Chem. Rev. 113 (1): 734–77. doi:10.1021/cr3002824. PMC 3764682. PMID 23121121.{{cite journal}}: CS1 maint: multiple names: authors list (link) Desiraju, G. R. (2013). "Crystal engineering: From molecule to crystal". J. Am. Chem. Soc. 135 (27): 9952–67. Bibcode:2013JAChS.135.9952D. doi:10.1021/ja403264c. PMID 23750552. Seto, C. T.; Whitesides, G. M. (1993). "Molecular self-assembly through hydrogen bonding: Supramolecular aggregates based on the cyanuric acid-melamine lattice". J. Am. Chem. Soc. 115 (3): 905–916. Bibcode:1993JAChS.115..905S. doi:10.1021/ja00056a014.{{cite journal}}: CS1 maint: multiple names: authors list (link)

The cap is 1.6–8 cm (3⁄4–3+1⁄4 in), conic to convex with a central papilla when young, becoming broadly convex to plane with age, retaining a slight umbo sometimes surrounded by a ring-shaped depression. The cap surface is smooth and sticky, sometimes with white universal veil remnants attached. The cap is brown becoming paler to almost white at the margin and fades to more golden-brown or yellowish with age. When bruised, all parts of the mushroom stain blue. The narrow grey gills are adnate to adnexed, sometimes seceding attachment, and darken to purplish-black and somewhat mottled with age. The gill edges remain whitish. The hollow white stipe is 4–15 cm (2–6 in) high by 0.4–1.4 cm (1⁄4–1⁄2 in) thick, becoming yellowish in age. The well-developed veil leaves a persistent white membranous ring whose surface usually becomes the same color as the gills because of falling spores. The fruiting bodies are 90% water. The mushroom has no odor and has been described as tasting farinaceous, with an alkaline or metallic aftertaste. The spores are 11.5–17.3 x 8–11.5 μm, sub-ellipsoid, basidia 4-spored but sometimes 2- or 3-, pleurocystidia and cheilocystidia present.

MALDI-TOF spectra are often used for the identification of microorganisms such as bacteria or fungi. A portion of a colony of the microbe in question is placed onto the sample target and overlaid with matrix. The mass spectra of expressed proteins generated are analyzed by dedicated software and compared with stored profiles for species determination in what is known as biotyping. It offers benefits to other immunological or biochemical procedures and has become a common method for species identification in clinical microbiological laboratories. Benefits of high resolution MALDI-MS performed on a Fourier transform ion cyclotron resonance mass spectrometry (also known as FT-MS) have been demonstrated for typing and subtyping viruses though single ion detection known as proteotyping, with a particular focus on influenza viruses. One main advantage over other microbiological identification methods is its ability to rapidly and reliably identify, at low cost, a wide variety of microorganisms directly from the selective medium used to isolate them. The absence of the need to purify the suspect or "presumptive" colony allows for a much faster turn-around times. For example, it has been demonstrated that MALDI-TOF can be used to detect bacteria directly from blood cultures. Another advantage is the potential to predict antibiotic susceptibility of bacteria. A single mass spectral peak can predict methicillin resistance of Staphylococcus aureus.

Sources: en.wikipedia.org

Reference notes

Although it remains uncertain as to who was involved in this incident, there has been immediate assertions that North Korea is connected, as it threatened to attack South Korea's government institutions, major national banks and traditional newspapers numerous times – in reaction to the sanctions it received from nuclear testing and to the continuation of Foal Eagle, South Korea's annual joint military exercise with the United States. North Korea's cyber warfare capabilities raise the alarm for South Korea, as North Korea is increasing its manpower through military academies specializing in hacking. Current figures state that South Korea only has 400 units of specialized personnel, while North Korea has more than 3,000 highly trained hackers; this portrays a huge gap in cyber warfare capabilities and sends a message to South Korea that it has to step up and strengthen its Cyber Warfare Command forces. Therefore, in order to be prepared from future attacks, South Korea and the United States will discuss further about deterrence plans at the Security Consultative Meeting (SCM). At SCM, they plan on developing strategies that focuses on accelerating the deployment of ballistic missiles as well as fostering its defense shield program, known as the Korean Air and Missile Defense.

A DNA construct is an artificially-designed segment of DNA borne on a vector that can be used to incorporate genetic material into a target tissue or cell. A DNA construct contains a DNA insert, called a transgene, delivered via a transformation vector which allows the insert sequence to be replicated and/or expressed in the target cell. This gene can be cloned from a naturally occurring gene, or synthetically constructed. The vector can be delivered using physical, chemical or viral methods. Typically, the vectors used in DNA constructs contain an origin of replication, a multiple cloning site, and a selectable marker. Certain vectors can carry additional regulatory elements based on the expression system involved. DNA constructs can be as small as a few thousand base pairs (kbp) of DNA carrying a single gene, using vectors such as plasmids or bacteriophages, or as large as hundreds of kbp for large-scale genomic studies using an artificial chromosome. A DNA construct may express wildtype protein, prevent the expression of certain genes by expressing competitors or inhibitors, or express mutant proteins, such as deletion mutations or missense mutations. DNA constructs are widely adapted in molecular biology research for techniques such as DNA sequencing, protein expression, and RNA studies.

=== Excessive intake === Excessive intake of potassium is not a primary cause of hyperkalemia because, in the presence of normal kidney function and the absence of drugs causing alterations in homeostasis, the kidney responds to the rise in potassium levels by increasing the excretion of potassium into urine. This is mediated by aldosterone hormone secretion and by increasing the number of potassium-secreting channels in kidney tubules. Acute hyperkalemia in infants is also rare, even though their body volume is small, with accidental ingestion of potassium salts or potassium medications. Hyperkalemia usually develops when there are other co-morbidities such as hypoaldosteronism and chronic kidney disease.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

Network